About 30,000 cases of lung cancer occur in Spain each year. Mutations in KRAS oncogenes account for 10-15% of these cases, a subgroup against which there are still no effective therapies. Researchers have succeeded in determining the structure of the RAF1 protein, a therapeutic target against cancers associated with KRAS oncogenes.
